Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of a Rotavirus Vaccine (Rotavin-M1) Among Healthy Adults

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~At dose 1~* Healthy male or female, 18 to 40 years of age,~* Free of disease,~* Written informed consent obtained from subjects. At dose 2~* Received dose 1.~* Oral informed consent obtained from subject for continuing participate the study.~Exclusion Criteria:~At dose 1~1. Pregnant woman or planning to be pregnant during the study period.~2. Has a chronic disease (cardiovascular, liver, kidney disease).~3. Acute disease at the time of enrolment.~4. Administering corticosteroids (\> 1mg/kg/day).~5. Received any immunosuppressive therapy within 4 week before vaccination (Administration of immunoglobulins and/or any blood product or corticosteroids for \>2 weeks).~6. Immunosuppressive or immunodeficient condition.~7. Allergic or reaction with any component of vaccine, includes anaphylactic and shock with any antibiotic.~8. Fever (axillary temperature \>38oC) within 3 days before or on the day of vaccination.~9. Has any type of blood disorder, leukemia, or malignant tumor which can affect the bone marrow or lymph system.~10. Use of any investigational or non-registered product (unlicensed drug or vaccine) other than the study vaccine during the study period.~At dose 2~1. Pregnant woman or planning to be pregnant in next 1 month.~2. Acute disease at the time of 2nd dose.~3. Administering corticosteroids (\> 1mg/kg/day).~4. Received any immunosuppressive therapy within 4 week before vaccination (administration of immunoglobulins and/or any blood product or corticosteroids for \>2 weeks).~5. Immunosuppressive or immunodeficient condition.~6. History of allergic disease or reactions likely to be exacerbated by any component of the study vaccine.~7. Fever (axillary temperature \>38oC) within 3 days before or on the day of vaccination.~8. Has any type of blood disorder, leukemia, or malignant tumor which can affect the bone marrow or lymph system.~9. Use of any investigational or non-registered product (unlicensed drug or vaccine) other than the study vaccine during the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Rotavin (Type: EXPERIMENTAL): Rotavin-M1 vaccine, 10e6.3FFU/dose, 2 doses, 1 month between doses

Based on this trial design, predict the completion outcome and termination type (if applicable).